Indrayani BiotechBOM:526445 -2.11%53 EBITDA Margin % is 10.34% as of Dec. 2025, which is 17% above its 10-year median of 8.84. GuruFocus rates BOM:526445 with a GF Score™ of 53/100 and a GF Value™ of ₹40.84 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,071 Business Services companies, Indrayani Biotech ranks worse than 66.39% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Indrayani Biotech's EBITDA for the
three
months ended in Dec. 2025 was ₹36 Mil. Indrayani Biotech's Revenue for the
three
months ended in Dec. 2025 was ₹350 Mil. Therefore, Indrayani Biotech's EBITDA margin for the quarter that ended in Dec. 2025 was 10.34%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Indrayani Biotech EBITDA Margin % Related Terms
Indrayani Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Indrayani Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:526445 vs CTAS, CPRT, ULS: EBITDA Margin % Comparison
For the Specialty Business Services subindustry, Indrayani Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indrayani Biotech EBITDA Margin % vs Business Services Industry
For the Business Services industry and Industrials sector, Indrayani Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Indrayani Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indrayani Biotech (BOM:526445) has a EBITDA Margin % of 10.34% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indrayani Biotech and its competitors. This is 17% above median its historical median of 8.84. According to the industry distribution chart, Indrayani Biotech ranks #711 out of 1071 companies in the Business Services industry, placing it in the top 66.4%.
Is Indrayani Biotech's EBITDA Margin % too high?
Indrayani Biotech's current EBITDA Margin % of 10.34% is 17% above median its 10-year median of 8.84. The Business Services industry median EBITDA Margin % is 10.93. Indrayani Biotech's value of 10.34% is 5.4% below this industry median. Based on the distribution chart, Indrayani Biotech ranks #711 out of 1071 companies in the Business Services industry, which is below the industry midpoint. Overall, Indrayani Biotech has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indrayani Biotech's EBITDA Margin % compare to CTAS and CPRT?
According to the Business Services industry distribution chart, Indrayani Biotech ranks #711 out of 1071 companies for EBITDA Margin %. This places Indrayani Biotech in the lower half of its industry. The industry median EBITDA Margin % is 10.93. Indrayani Biotech's value of 10.34% is 5.4% below this benchmark. While the company's 10-year median is 8.84 vs. the industry median of 10.93, Indrayani Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Business Services company?
The median EBITDA Margin % among Business Services companies is 10.93, based on 1,071 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indrayani Biotech's current EBITDA Margin % of 10.34% is 5.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Indrayani Biotech and its competitors. For the Business Services industry, the median EBITDA Margin % is 10.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indrayani Biotech's current EBITDA Margin % is 10.34%, which is 17% above median its own 10-year median of 8.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indrayani Biotech stock overvalued right now?
Based on GuruFocus' analysis, Indrayani Biotech (BOM:526445) is currently considered Possible Value Trap. The stock's GF Value™ is ₹40.84, compared to a current price of ₹8.81 — trading 78.4% below its estimated fair value. The current EBITDA Margin % is 10.34%, which is 17% above median its 10-year median of 8.84 and 5.4% below the Business Services industry median of 10.93. Indrayani Biotech's overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Indrayani Biotech (BOM:526445), the current EBITDA Margin % is 10.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indrayani Biotech (BOM:526445) Overvalued in 2026?
Based on GuruFocus' analysis, Indrayani Biotech stock appears to be undervalued.
The current stock price of ₹8.81 is trading 78.4% below its estimated GF Value™ of ₹40.84.
GuruFocus considers Indrayani Biotech to be Possible Value Trap.
Key valuation signals for BOM:526445:
EBITDA Margin %: 10.34% (17% above median its 10-year median of 8.84)
GF Value™: ₹40.84 vs. price of ₹8.81 (78.4% below fair value)
Industry Position: 5.4% below the Business Services median (#711 of 1071)
No single metric tells the full story. See the BOM:526445 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indrayani Biotech Ltd operates in the Tri-segment i.e. Foods & Hospitality, Engineering and Healthcare divisions. The company generates its revenue from the sale of food, beverages, and other items; the Sale of Engineering products & Others. The majority of its revenue is generated from the sale of food, beverages, and other items.
53GF Score
Get the complete analysis for BOM:526445
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:526445 has been successfully added to your 
